Half Life Extended (HLE) Bispecific T cell engager (BiTE®)
Showing 1 - 25 of >10,000
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in Worldwide (acapatamab, Pembrolizumab, Etanercept)
Active, not recruiting
- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- acapatamab
- +3 more
-
Campbell, California
- +29 more
Dec 6, 2022
Small Cell Lung Carcinoma Trial in Worldwide (AMG 757, Pembrolizumab, CRS Mitigation Strategies)
Recruiting
- Small Cell Lung Carcinoma
- AMG 757
- +2 more
-
Duarte, California
- +34 more
Dec 6, 2022
MUC17-positive Solid Tumors Trial in Worldwide (AMG 199)
Recruiting
- MUC17-positive Solid Tumors
- AMG 199
-
Duarte, California
- +20 more
Feb 23, 2022
Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)
Not yet recruiting
- Malignant Glioma
- Glioblastoma
- hEGFRvIII-CD3 (BRiTE)
- Activated Cell Therapy
-
Durham, North CarolinaDuke University Medical Center
Jun 24, 2022
Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Acapatamab, Enzalutamide, Abiraterone)
Active, not recruiting
- Metastatic Castration-resistant Prostate Cancer
- Acapatamab
- +3 more
-
Birmingham, Alabama
- +13 more
Jun 20, 2022
Colorectal Cancer Trial (Administration of CC-3)
Not yet recruiting
- Colorectal Cancer
- Administration of CC-3
- (no location specified)
Aug 11, 2023
Hepatitis B, Chronic Trial in Worldwide (IMC-I109V-101 Single Ascending Dose, IMC-I109V-101 Multiple Ascending Doses)
Recruiting
- Hepatitis B, Chronic
- IMC-I109V-101 Single Ascending Dose
- IMC-I109V-101 Multiple Ascending Doses
-
Los Angeles, California
- +19 more
May 10, 2023
B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Apr 4, 2022
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Lung Cancer Squamous Cell Trial in Stuttgart, Tuebingen (CC-1 and Toczilizumab)
Recruiting
- Lung Cancer Squamous Cell
- CC-1 and Toczilizumab
-
Stuttgart, BW, Germany
- +1 more
Feb 2, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Trial in Israel, United States (Blinatumomab,
Recruiting
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Blinatumomab
- +10 more
-
Anchorage, Alaska
- +152 more
Aug 11, 2022
Advanced Malignancies Trial in Beijing (1A46 Drug Substance)
Not yet recruiting
- Advanced Malignancies
- 1A46 Drug Substance
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 4, 2023
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult Trial in Germany (IMA402 (Phase Ia), IMA402 (Phase Ib), IMA402 (Phase
Not yet recruiting
- Refractory Cancer
- +3 more
- IMA402 (Phase Ia)
- +2 more
-
Heidelberg, Baden-Wuerttemberg, Germany
- +12 more
Jul 14, 2023
NSCLC, Solid Tumor Trial in Tianjin (HS-20117)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Solid Tumor
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 10, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023